Trial reportMedicine2025
Effects of erythromycin dosage on clinical outcomes in stable non-cystic fibrosis bronchiectasis: A randomized controlled trial.
Trial report in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThis study evaluates the efficacy and side effects of different doses of erythromycin in patients with stable non-cystic fibrosis bronchiectasis (NCFB).
methodsAltogether, 148 patients diagnosed with stable NCFB were enrolled in this study and randomly assigned to one of the following 4 treatment groups: Group A received erythromycin 250 mg/d; Group B received erythromycin 375 mg/d; Group C received erythromycin 500 mg/d; and Group D received a placebo. Each group consisted of 35 patients. The dataset comprised lung function data and computed tomography, St. George respiratory questionnaire, modified Medical Research Council, bronchiectasis severity index (BSI), and exacerbations, FEV1, age, chronic colonization, extension, dyspnea scores, which were collected before and at 6 months after treatment. These were subjected to a univariate analysis.
resultsGroups C and D exhibited significant differences in forced expiratory volume in 1 second, forced vital capacity, quality of life, and computed tomography Bhalla, BSI, and E-FACED scores (P < .05). Additionally, Groups B and D demonstrated significant differences in forced vital capacity and St. George respiratory questionnaire, BSI, and E-FACED scores (P < .05). Contrarily, Group A exhibited nonsignificant differences.
conclusionThe oral erythromycin regimen at a dose of 500 mg/d can improve the lung function and quality of life of stable NCFB patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.